Beyond β-Blockade: ACE Inhibitors Reduce Non-Cardiac Mortality in High Killip Grade AMI Patients

Area of Science:

• Cardiology
• Clinical Medicine
• Pharmacology

Background:

• High Killip grade (III/IV) acute myocardial infarction (AMI) indicates severe cardiac dysfunction and carries a poor prognosis.
• Optimal medical therapy for these high-risk patients is crucial for improving clinical outcomes.
• Comparing angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in combination with beta-blockers (BB) is important for guiding treatment decisions.

Purpose of the Study:

• To evaluate and compare the 3-year clinical outcomes of high Killip grade AMI patients treated with either BB + ACEI or BB + ARB.
• To determine if one regimen offers superior protection against major adverse cardiac events and mortality.

Main Methods:

• A cohort of 871 high Killip grade AMI patients from the Korea Acute Myocardial Infarction Registry (KAMIR-NIH) was analyzed.
• Patients were divided into two groups: BB + ACEI (n=489) and BB + ARB (n=381).
• Propensity score matching was used to select 343 patients for each group, ensuring comparable baseline characteristics for a 3-year follow-up.

Main Results:

• While no significant differences were observed in cardiac death, recurrent MI, or repeat PCI rates between the groups, the BB + ACEI group showed significantly lower risks.
• The BB + ACEI group had a reduced risk of major adverse cardiac events (HR=0.574, p<.001), all-cause mortality (HR=0.561, p=.001), and non-cardiac death (HR=0.365, p<.001).

Conclusions:

• Beta-blockers plus angiotensin-converting enzyme inhibitors (BB + ACEI) appear to be more beneficial than BB + angiotensin receptor blockers (BB + ARB) for patients with high Killip grade AMI.
• The BB + ACEI regimen demonstrated a superior preventative effect on mortality in this high-risk AMI population over a 3-year period.